WASHINGTON — Jan. 2024 — DIA, a global organization of life sciences professionals, will host a series of discussions regarding the ethical and responsible use of artificial intelligence (AI) in health care during its annual Global Pharmacovigilance and Risk Management Strategies Conference from Feb. 5-7 at the Baltimore Marriott Waterfront hotel in Baltimore.

The conference will unite regulators and life sciences experts to discuss the latest developments, opportunities, and challenges facing safety professionals, especially as AI transforms treatment options and overall patient care.

Dr. Michael Ybarra, Senior Vice President and Chief Medical Officer at the Pharmaceutical Research and Manufacturers of America (PhRMA), and an Assistant Professor of Emergency Medicine at Georgetown University School of Medicine, will begin the conference on Feb. 5 with his keynote address, "Personalized Medicine and the Pharmaceutical Industry."

Attendees will also hear from Dr. Gerald J. Dal Pan, the Director of the Office of Surveillance and Epidemiology at the Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research, and Dr. Emil Cochino, the Scientific Senior Specialist for Risk Management at the European Medicines Agency (EMA). Their presentations will provide the latest guidance on good pharmacovigilance practices — especially as they pertain to incorporating AI — and empower those in attendance with direction and insight from two leading regulatory agencies.

Two other can't-miss conversations will take place. "Application and Use of Machine Learning, Artificial Intelligence, Automation, and Technology in Pharmacovigilance" will explore the impact of technologies such as generative AI and offer attendees insights into its practical application in pharmacovigilance. "Insights into the Collection of Safety Data in Pregnancy" will delve into ethical issues surrounding the inclusion of pregnant women in trials, identify key requirements for evaluating drug safety in pregnancy, and share lessons from prior safety data collection in pregnancy.

Additionally, the conference will cover a diverse range of topics, including safety management for advanced therapies, providing insights into addressing unique challenges associated with these types of treatments. Attendees can expect discussions on the Council for International Organizations of Medical Sciences (CIOMS) Working Group XII Benefit-Risk Balance for Medicinal Products report, offering valuable perspectives on the latest developments and recommendations in benefit-risk assessment methodologies.

The program will also delve into the global evolution of risk minimization requirements and solutions and explore the use of real-world data and evidence for robust safety surveillance programs.

Register for the Global Pharmacovigilance and Risk Management Strategies Conference